BDNF and Huntington disease: At earlier stages of HD, the use of SCH58261 (an A2A receptor antagonist) in quinolinic acid (QA)-induced HD rats and R6/2 transgenic mice reduced striatal BDNF expression, precluding BDNF control of NMDA toxicity (Potenza et al., 2007; Tebano et al., 2010).